Orthocell sees four patients benefit from CelGro trial

Company News

by Rachael Jones

Regenerative medicine company Orthocell (ASX:OCC) have seen the first four patients successfully complete participation in the CelGro® nerve regeneration clinical trial.

Following surgery with CelGro®, patients have regained muscle function and/or sensation of affected limbs and have returned to work, sport and activities of daily living.

The patients had previously suffered traumatic peripheral nerve injuries following motor vehicle, sporting and work-related incidents, resulting in complete paralysis, or impaired use of the upper limb.

Shares in Orthocell (ASX:OCC) closed flat at 11.5 cents yesterday.


Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.